Senti Bio Shares Catapult After $37.6M Private Placement, Positive Phase 1 Trial

Dow Jones2024-12-03

By Sarina Isaacs

Shares of Senti Biosciences soared on an oversubscribed private placement and positive early results for a proposed blood cancer treatment.

The stock climbed 437% to $11.59 in late-morning trading, and earlier was up nearly eightfold to $16.94, prompting a pause in trading due to volatility.

The South San Francisco, Calif.-based developer of cell and gene therapies said Monday that it inked a securities purchase agreement with certain investors for a private placement of 16,713 convertible preferred shares, for gross proceeds of about $37.6 million. The financing is expected to close by Dec. 5.

Senti also said investors will have the right to exercise warrants to buy up to about another 25.1 million shares of common stock, upon shareholder approval, and that a certain investor will have the option to pick up another 4,444 shares of preferred stock and accompanying warrants for about $10 million in gross proceeds.

The private placement financing was led by Celadon Partners.

The company additionally said Monday that, in a phase 1 trial for its gene circuit platform for treatment of acute myeloid leukemia and other relapsed/refractory hematologic malignancies, two of three patients achieved complete remission. The patients remain in remission three and four months later, the company said.

Senti added that the administered dose had a generally well-tolerated preliminary safety profile, and that further data is expected next year after continuing dose escalation.

Write to Sarina Isaacs at sarina.isaacs@wsj.com

(END) Dow Jones Newswires

December 02, 2024 11:36 ET (16:36 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488605180?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-03 00:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488605180","market":"hk","top_or_hot":-1,"title":"Senti Bio Shares Catapult After $37.6M Private Placement, Positive Phase 1 Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sarina Isaacs \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Senti Biosciences soared on an oversubscribed private placement and positive early results for a proposed blood cancer treatment. \n</p>\n<p>\n  The stock climbed 437% to $11.59 in late-morning trading, and earlier was up nearly eightfold to $16.94, prompting a pause in trading due to volatility. \n</p>\n<p>\n  The South San Francisco, Calif.-based developer of cell and gene therapies said Monday that it inked a securities purchase agreement with certain investors for a private placement of 16,713 convertible preferred shares, for gross proceeds of about $37.6 million. The financing is expected to close by Dec. 5. \n</p>\n<p>\n  Senti also said investors will have the right to exercise warrants to buy up to about another 25.1 million shares of common stock, upon shareholder approval, and that a certain investor will have the option to pick up another 4,444 shares of preferred stock and accompanying warrants for about $10 million in gross proceeds. \n</p>\n<p>\n  The private placement financing was led by Celadon Partners. \n</p>\n<p>\n  The company additionally said Monday that, in a phase 1 trial for its gene circuit platform for treatment of acute myeloid leukemia and other relapsed/refractory hematologic malignancies, two of three patients achieved complete remission. The patients remain in remission three and four months later, the company said. \n</p>\n<p>\n  Senti added that the administered dose had a generally well-tolerated preliminary safety profile, and that further data is expected next year after continuing dose escalation. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sarina Isaacs at sarina.isaacs@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 02, 2024 11:36 ET (16:36 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Senti Bio Shares Catapult After $37.6M Private Placement, Positive Phase 1 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSenti Bio Shares Catapult After $37.6M Private Placement, Positive Phase 1 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-03 00:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Sarina Isaacs \n\n\n \n\n\n  Shares of Senti Biosciences soared on an oversubscribed private placement and positive early results for a proposed blood cancer treatment. \n\n\n  The stock climbed 437% to $...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2488605180","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488605180","pubTimestamp":1733157360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Senti Biosciences soared on an oversubscribed private placement and positive early results for a proposed blood cancer treatment.The stock climbed 437% to $11.59 in late-morning trading, and earlier was up nearly eightfold to $16.94, prompting a pause in trading due to volatility.The South San Francisco, Calif.-based developer of cell and gene therapies said Monday that it inked a securities purchase agreement with certain investors for a private placement of 16,713 convertible preferred shares, for gross proceeds of about $37.6 million. The financing is expected to close by Dec. 5.Senti also said investors will have the right to exercise warrants to buy up to about another 25.1 million shares of common stock, upon shareholder approval, and that a certain investor will have the option to pick up another 4,444 shares of preferred stock and accompanying warrants for about $10 million in gross proceeds.The private placement financing was led by Celadon Partners.Senti added that ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SNTI":"Senti Biosciences, Inc.","BK4539":"次新股"},"translate_title":"Senti Bio在3760万美元私募后股价飙升，第一阶段试验取得积极进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNTI":0.9},"content_text":"By Sarina Isaacs \n\n\n \n\n\n  Shares of Senti Biosciences soared on an oversubscribed private placement and positive early results for a proposed blood cancer treatment. \n\n\n  The stock climbed 437% to $11.59 in late-morning trading, and earlier was up nearly eightfold to $16.94, prompting a pause in trading due to volatility. \n\n\n  The South San Francisco, Calif.-based developer of cell and gene therapies said Monday that it inked a securities purchase agreement with certain investors for a private placement of 16,713 convertible preferred shares, for gross proceeds of about $37.6 million. The financing is expected to close by Dec. 5. \n\n\n  Senti also said investors will have the right to exercise warrants to buy up to about another 25.1 million shares of common stock, upon shareholder approval, and that a certain investor will have the option to pick up another 4,444 shares of preferred stock and accompanying warrants for about $10 million in gross proceeds. \n\n\n  The private placement financing was led by Celadon Partners. \n\n\n  The company additionally said Monday that, in a phase 1 trial for its gene circuit platform for treatment of acute myeloid leukemia and other relapsed/refractory hematologic malignancies, two of three patients achieved complete remission. The patients remain in remission three and four months later, the company said. \n\n\n  Senti added that the administered dose had a generally well-tolerated preliminary safety profile, and that further data is expected next year after continuing dose escalation. \n\n\n \n\n\n  Write to Sarina Isaacs at sarina.isaacs@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 02, 2024 11:36 ET (16:36 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488605180"}